What is ARS Pharmaceuticals, Inc.'s (SPRY) StockRank?

MoatMap's StockRank for ARS Pharmaceuticals, Inc. (SPRY) is 10/100, with a Strong Sell signal. This is a composite score combining Quality (22), Value (33), and Momentum (39) factor ranks across MoatMap's 19,000+ stock universe.

Does ARS Pharmaceuticals, Inc. have an economic moat?

ARS Pharmaceuticals, Inc. (SPRY) has a Quality factor score of 22/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is ARS Pharmaceuticals, Inc. a buy, hold, or sell?

MoatMap's current signal for ARS Pharmaceuticals, Inc. (SPRY) is Strong Sell, based on a StockRank of 10/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is ARS Pharmaceuticals, Inc. in?

ARS Pharmaceuticals, Inc. (SPRY) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

SPRY

STRONG SELLREMOVE

ARS Pharmaceuticals, Inc. · Healthcare · United States · $933M · Avg Vol: $17M/d

StockRank

P/E (TTM)

—

ROE

-136.4%

D/E

2.8x

Dividend %

—

Director Trades · 180d

−$283.6K →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

ARS Pharmaceuticals is a single-product biotech company awaiting broader commercial adoption of Neffy. It lacks the diversified cash flows, high ROIC, and long reinvestment runway of a quality compounder, presenting binary regulatory and adoption risks.

COMPANY DESCRIPTION

ARS Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for severe allergic reactions, including anaphylaxis. Its lead product candidate, neffy, is an innovative intranasal epinephrine spray designed to offer a needle-free and convenient alternative to existing injectable treatments. The company aims to address a critical unmet medical need by providing a potentially more accessible and user-friendly emergency treatment option.

FINANCIAL SUMMARY

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	1M	30,000	89M	84M	300.1%
EPS	—	-0.87	-0.57	0.08	-1.74	—
Shares	—	94M	96M	98M	99M	+5.7%
Debt	5M	481,000	274,000	42,000	96M	110.3%
Equity	—	273M	231M	257M	114M	-25.2%
Op CF	—	-40M	-59M	14M	-171M	—
Inv CF	—	-199,000	-87M	-106M	57M	—
Fin CF	—	191M	7M	72M	105M	—

PRICE (1M)+11.1%

SMA 50SMA 200

$9.81

RSI (14)

66.5

52W High

$18.90

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-58.5%11.5

ROE

-136.4%5.5

GP/Assets

17.9%42.1

Op. Margin

-265.2%12.7

FCF/Assets

-30.0%9.7

Piotroski

—28.8

Int. Cover

-50.0x6.5

D/E Ratio

2.79x3.7

Current Ratio

4.94x70.3

Value

P/E (TTM)

—N/A

EV/EBITDA

-4.7x72.3

P/FCF

—N/A

P/B

8.5x12.7

P/S

9.8x26.6

Div Yield

—N/A

Momentum

52W High %

52%26.1

RS 6M

-21%54.7

SMA 50/200

0.90x34.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+52%54.6

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$933M

P/E (Forward)

-10.2x

Gross Margin

59.4%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SPRY are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
SPRY	ARS Pharmaceuticals, Inc.(you)	$933M	10	STRONG SELL
OLMA	Olema Pharmaceuticals, Inc.	$1.1B	9	STRONG SELL
AKTS	Aktis Oncology, Inc.	$1.1B	9	STRONG SELL
EYPT	EyePoint, Inc.	$1.1B	8	STRONG SELL
JANX	Janux Therapeutics, Inc.	$899M	15	STRONG SELL
XNCR	Xencor, Inc.	$887M	16	STRONG SELL
SANA	Sana Biotechnology, Inc.	$871M	4	STRONG SELL
EVMN	Evommune, Inc.	$840M	15	STRONG SELL
DRUG	Bright Minds Biosciences Inc.	$878M	16	STRONG SELL
BBOT	BridgeBio Oncology Therapeutics, Inc.	$708M	12	STRONG SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.2%

ARS Pharmaceuticals, Inc. (SPRY) — Stock Score Summary

ARS Pharmaceuticals, Inc. (SPRY) has a MoatMap StockRank of 10/100 based on Quality (22/100), Value (33/100), and Momentum (39/100) factor scores. The current signal is STRONG SELL. ARS Pharmaceuticals is a single-product biotech company awaiting broader commercial adoption of Neffy. It lacks the diversified cash flows, high ROIC, and long reinvestment runway of a quality compounder, presenting binary regulatory and adoption risks.

Key Financial Metrics

Price	$9.81
Market Cap	$933M
P/E (Forward)	-10.19
Price/Book	8.48
Return on Equity	-136.4%
Return on Invested Capital	-58.5%
Debt/Equity	279.24
Gross Margin	59.4%
Operating Margin	-265.2%
Revenue Growth	184.5%
Free Cash Flow	$-98M

ARS Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is ARS Pharmaceuticals, Inc.’s (SPRY) StockRank?: MoatMap’s StockRank for ARS Pharmaceuticals, Inc. (SPRY) is 10/100, with a Strong Sell signal. It is a composite of Quality (22), Value (33), and Momentum (39) factor ranks across MoatMap’s 19,000+ stock universe.
Does ARS Pharmaceuticals, Inc. have an economic moat?: ARS Pharmaceuticals, Inc. (SPRY) has a Quality factor score of 22/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is ARS Pharmaceuticals, Inc. a buy, hold, or sell?: MoatMap’s current signal for ARS Pharmaceuticals, Inc. (SPRY) is Strong Sell, based on a StockRank of 10/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is ARS Pharmaceuticals, Inc. in?: ARS Pharmaceuticals, Inc. (SPRY) operates in the Healthcare sector, specifically the Biotechnology industry (United States).